You are here: Industry Insights > Pfizer

News List

Pfizer Japan drawn into valsartan recall after finding API from Mylan is tainted fiercepharma
February 24, 2019
The global recall of valsartan has now extended to Pfizer and to Japan, via Mylan and India.
Pfizer dethrones AbbVie as Xeljanz soars past Humira in January TV spending fiercepharma
February 24, 2019
New year, new leader on the pharma TV ad spending board. In January, Pfizer’s Xeljanz topped AbbVie's Humira in a rare bypass of the usual No. 1, spending more than $40 million on national TV time.
Pfizer, Merck, J&J well-positioned for M&A and Biogen and BioMarin are prime targets fiercepharma
February 24, 2019
This year is already shaping up to be a big one for biopharma mergers and acquisitions, with Bristol-Myers Squibb’s planned $74 billion buyout of Celgene well underway. But analysts at Morningstar are predicting the BMS-Celgene deal will mark the beginnin
Pfizer switches RA patients to lower dose of fast-growing Xeljanz as safety issues arise in postmarketing study fiercepharma
February 24, 2019
Pfizer has been battling it out against rivals in arthritis and ulcerative colitis with its Xeljanz, and its drug has been posting big sales gains.
Not ready to quit smoking cold turkey? Pfizer offers 'slow turkey' campaign for Chantix fiercepharma
February 24, 2019
Pfizer is introducing a new way to quit smoking.
Patients switch to lower dose of Pfizer’s RA pill after safety signal pharmaphorum
February 22, 2019
Pfizer is moving rheumatoid arthritis patients to a lower dose of its blockbuster inflammatory diseases pill Xeljanz in a clinical study, after a safety signal emerged in the trial of patients at high risk of cardiovascular events.
More positive results for Pfizer/Lilly’s non-opioid pain drug pharmaphorum
February 22, 2019
Pfizer and Eli Lilly have announced more positive results from a phase 3 study of their non-opioid pain drug tanezumab, this time in chronic lower back pain (CBLP).
Between Merck and Pfizer, the race is on in kidney cancer—but analysts are calling it early fiercepharma
February 20, 2019
The race is on between two Big Pharmas to snag a new indication in kidney cancer, but thanks to new data from Merck & Co., it may not matter who gets there first.
Pfizer, Lilly Announce Top-line Results from Tanezumab Phase 3 Study americanpharmaceuticalreview
February 20, 2019
Pfizer and Eli Lilly and Company announced positive top-line results from a Phase 3 study evaluating tanezumab in patients with moderate-to-severe chronic low back pain (CLBP)....
Merck Group and Pfizer announce positive results for combo therapy for RCC pharmaceutical-technology
February 19, 2019
Pfizer and German-based Merck Group have published promising interim results from their Phase III JAVELIN Renal 101 trial evaluating the efficacy and safety of ....

Previous page 1 2 3 4 5 6 7 8 9 10 ... 83 84 Next page